{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:35:55Z","timestamp":1793104555769,"version":"4.5.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The 4\u201312 week lag period of conventional antidepressants creates critical vulnerability in severe depression, with peak suicide risk during the first month. While ketamine research has focused on treatment-resistant populations, its potential to eliminate this lag period in non-treatment-resistant severe depression remains unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To evaluate whether add-on intravenous ketamine eliminates the treatment lag period in severe non-treatment-resistant major depressive disorder and assess rapid antidepressant and anti-suicidal effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A randomized, double-blind, placebo-controlled trial was conducted at a tertiary care hospital from October 2020 to September 2022. Forty patients with severe MDD (HAM-D \u226519) received either ketamine (0.5 mg\/kg IV, n = 19) or placebo (n = 21) as add-on therapy over 4 infusions on days 1, 3, 5, and 8. The primary outcome was \u226550% HAM-D reduction at day 12. Secondary outcomes included suicidal ideation using the Beck Scale for Suicidal Ideation (BSSI) and global functioning improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Primary response rate was 58% versus 29% in placebo (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05), yielding a number needed to treat of 3.4. Significant HAM-D improvement occurred from day 2 onwards (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Complete suicidal ideation resolution occurred by day 5 in the ketamine group versus persistent ideation in placebo (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Patients with anxiety features showed 0% treatment completion versus 93% in non-anxious patients. Effects were sustained at 4-week follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This pilot randomized controlled trial provides preliminary evidence for rapid antidepressant and anti-suicidal effects of add-on intravenous ketamine in severe non-treatment-resistant major depression; findings require confirmation in an adequately powered trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/indianjpsychiatry_845_25","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:00:46Z","timestamp":1789632046000},"page":"776-783","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Add-on intravenous ketamine eliminates treatment lag period in severe non-treatment-resistant major depression: Rapid antidepressant and anti-suicidal effects \u2013 A randomized controlled trial"],"prefix":"10.4103","volume":"68","author":[{"given":"Anand","family":"Prakash","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Kalinga Institute of Medical Sciences (KIMS), KIIT University, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranab","family":"Mahapatra","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kalinga Institute of Medical Sciences (KIMS), KIIT University, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigyansa I.","family":"Pattnaik","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kalinga Institute of Medical Sciences (KIMS), KIIT University, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udit K.","family":"Panda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kalinga Institute of Medical Sciences (KIMS), KIIT University, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipta K.","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kalinga Institute of Medical Sciences (KIMS), KIIT University, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"R3-20261027","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/jama.292.3.338","article-title":"Antidepressants and the risk of suicidal behaviors","volume":"292","author":"Jick","year":"2004","journal-title":"JAMA"},{"key":"R4-20261027","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1176\/appi.ajp.163.1.41","article-title":"Suicide risk during antidepressant treatment","volume":"163","author":"Simon","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R5-20261027","doi-asserted-by":"crossref","first-page":"946","DOI":"10.4088\/JCP.v69n0610","article-title":"Rapid onset of antidepressant action: A new paradigm in the research and treatment of major depressive disorder","volume":"69","author":"Machado-Vieira","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R6-20261027","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R7-20261027","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"R8-20261027","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R9-20261027","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat Med"},{"key":"R10-20261027","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"R11-20261027","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am J Psychiatry"},{"key":"R12-20261027","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am J Psychiatry"},{"key":"R13-20261027","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/da.22253","article-title":"Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression","volume":"31","author":"Price","year":"2014","journal-title":"Depress Anxiety"},{"key":"R14-20261027","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am J Psychiatry"},{"key":"R15-20261027","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/archpsyc.1984.01790190056007","article-title":"Identification of true drug response to antidepressants: Use of pattern analysis","volume":"41","author":"Quitkin","year":"1984","journal-title":"Arch Gen Psychiatry"},{"key":"R16-20261027","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0924-977X(93)90264-M","article-title":"Time course of improvement under antidepressant treatment: A survival-analytical approach","volume":"3","author":"Stassen","year":"1993","journal-title":"Eur Neuropsychopharmacol"},{"key":"R17-20261027","doi-asserted-by":"crossref","first-page":"1011103","DOI":"10.3389\/fnins.2022.1011103","article-title":"The effect of ketamine on cognition, anxiety, and social functioning in adults with psychiatric disorders: A systematic review and meta-analysis","volume":"16","author":"Marchi","year":"2022","journal-title":"Front Neurosci"}],"container-title":["Indian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/indianjpsychiatry_845_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:01:42Z","timestamp":1793102502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/indianjpsychiatry_845_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/indianjpsychiatry_845_25","relation":{},"ISSN":["0019-5545","1998-3794"],"issn-type":[{"value":"0019-5545","type":"print"},{"value":"1998-3794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2025-08-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}